Valion Bio (VBIO) closed at $0.51 on November 12, 2026, up 1.1% from the previous close, on volume of 63,237 shares (30-day average 1,208,986).
Data as of November 12, 2026.
ACCESS Newswire (Wed, 11-Nov 8:10 AM ET)
Valion Bio Announces Series B Preferred Stock Financing
TipRanks (Mon, 9-Nov 6:34 AM ET)
ACCESS Newswire (Fri, 30-Oct 7:50 AM ET)
ACCESS Newswire (Wed, 28-Oct 7:45 AM ET)
Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options
ACCESS Newswire (Mon, 26-Oct 8:00 AM ET)
ACCESS Newswire (Wed, 21-Oct 8:00 AM ET)
Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone
ACCESS Newswire (Thu, 15-Oct 8:00 AM ET)
ACCESS Newswire (Wed, 14-Oct 8:15 AM ET)
ACCESS Newswire (Fri, 9-Oct 7:47 AM ET)
ACCESS Newswire (Mon, 5-Oct 8:30 AM ET)
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.
Valion Bio trades on the NASDAQ stock market under the symbol VBIO.
As of November 13, 2026, VBIO stock price declined to $0.48 with 17,955 million shares trading.
VBIO has a beta of 3.92, meaning it tends to be more sensitive to market movements. VBIO has a correlation of 0.08 to the broad based SPY ETF.
VBIO has a market cap of $1.01 million. This is considered a Sub-Micro Cap stock.
VBIO support price is $.47 and resistance is $.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VBIO shares will trade within this expected range on the day.
